
    
      A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics
      and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients with EGFR Mutation
      Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC) who failed standard treatment and
      developed brain or leptomeningeal diseases
    
  